{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:28:50Z","timestamp":1777120130069,"version":"3.51.4"},"reference-count":43,"publisher":"The Journal of Rheumatology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2023,10,5]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Patients with axial spondyloarthritis (axSpA) in clinical remission tapered tumor necrosis factor inhibitor (TNFi) therapy according to a clinical guideline. Over a 2-year follow-up period, we aimed to investigate flare frequency, dose at which flare occurred, type of flare, and predictors thereof.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients in clinical remission (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] &lt; 40, physician global score &lt; 40, and without disease activity the previous year) tapered TNFi to two-thirds the standard dose at baseline, half at week 16, one-third at week 32, and discontinued at week 48. Flares were defined as BASDAI flare (BASDAI \u2265 40 and change \u2265 20 since inclusion), and\/or clinical flare (development of inflammatory back pain, musculoskeletal or extraarticular manifestations, and\/or Ankylosing Spondylitis Disease Activity Score [ASDAS] \u2265 0.9), and\/or magnetic resonance imaging (MRI) flare (\u2265 2 new or worsened inflammatory lesions).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 108 patients, 106 (99%) flared before 2-year follow-up: 29 patients (27%) at two-thirds standard dose, 21 (20%) at half dose, 29 (27%) at one-third dose, and 27 (25%) after discontinuation. Regarding type of flare, 105 (99%) had clinical flares, 25 (24%) had BASDAI flares, and 23 (29% of patients with MRI at flare available) had MRI flares. Forty-one patients (41%) fulfilled the Assessment of SpondyloArthritis international Society (ASAS) definition of clinically important worsening (\u2265 0.9 increase since baseline). Higher baseline physician global score was an independent predictor of flare after tapering to two-thirds (OR 1.19, 95% CI 1.04-1.41,<jats:italic>P<\/jats:italic>= 0.01). Changes in clinical and\/or imaging variables in the 16 weeks prior to tapering did not predict flare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Almost all (99%) patients with axSpA in clinical remission experienced flare during tapering to discontinuation, but in over half of these patients, flare did not occur before receiving one-third dose or less. Higher physician global score was an independent predictor of flare.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.2023-0495","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:20:17Z","timestamp":1697372417000},"page":"39-49","source":"Crossref","is-referenced-by-count":6,"title":["Occurrence and Prediction of Flare After Tapering of Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis"],"prefix":"10.3899","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2095-9441","authenticated-orcid":false,"given":"Marie","family":"Wetterslev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-9457","authenticated-orcid":false,"given":"Stylianos","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-9932","authenticated-orcid":false,"given":"Sara Nysom","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-9263","authenticated-orcid":false,"given":"Susanne Juhl","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Juul","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Duer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"Boesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasper Kj\u00e6rulf","family":"Gosvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-6494","authenticated-orcid":false,"given":"Jakob M\u00f8llenbach","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Bakkegaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1790-5610","authenticated-orcid":false,"given":"Cecilie Heegaard","family":"Brahe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels Steen","family":"Krogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bente","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Rintek","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesper","family":"N\u00f8rregaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"R\u00f8gind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2023,10,15]]},"reference":[{"key":"2024030708001980000_51.1.39.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31591-4"},{"key":"2024030708001980000_51.1.39.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210770"},{"key":"2024030708001980000_51.1.39.3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/art.39298","article-title":"American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024030708001980000_51.1.39.4","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"2024030708001980000_51.1.39.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31362-X"},{"key":"2024030708001980000_51.1.39.6","doi-asserted-by":"crossref","first-page":"rkaa015","DOI":"10.1093\/rap\/rkaa015","article-title":"Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study","volume":"4","author":"Van Rossen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2024030708001980000_51.1.39.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1722-5"},{"key":"2024030708001980000_51.1.39.8","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S99490"},{"key":"2024030708001980000_51.1.39.9","first-page":"2398","article-title":"Tapering of TNF inhibitors in axial spondyloarthritis in routine care - 2-year clinical and MRI outcomes and predictors of successful tapering","volume":"61","author":"Wetterslev","year":"2022","journal-title":"Rheumatology"},{"key":"2024030708001980000_51.1.39.10","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2024030708001980000_51.1.39.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2024030708001980000_51.1.39.12","first-page":"946","article-title":"A modification of the Health Assessment Questionnaire for the Spondyloarthropathies","volume":"17","author":"Daltroy","year":"1990","journal-title":"J Rheumatol"},{"key":"2024030708001980000_51.1.39.13","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2024030708001980000_51.1.39.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203967"},{"key":"2024030708001980000_51.1.39.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21445"},{"key":"2024030708001980000_51.1.39.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140519"},{"key":"2024030708001980000_51.1.39.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201075"},{"key":"2024030708001980000_51.1.39.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.21337"},{"key":"2024030708001980000_51.1.39.19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001057"},{"key":"2024030708001980000_51.1.39.20","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000624"},{"key":"2024030708001980000_51.1.39.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090618"},{"key":"2024030708001980000_51.1.39.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090618"},{"key":"2024030708001980000_51.1.39.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090619"},{"key":"2024030708001980000_51.1.39.24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090619"},{"key":"2024030708001980000_51.1.39.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2024030708001980000_51.1.39.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020503"},{"key":"2024030708001980000_51.1.39.27","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3177"},{"key":"2024030708001980000_51.1.39.28","doi-asserted-by":"publisher","DOI":"10.1186\/ar1693"},{"key":"2024030708001980000_51.1.39.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew033"},{"key":"2024030708001980000_51.1.39.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"2024030708001980000_51.1.39.31","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2571-5"},{"key":"2024030708001980000_51.1.39.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201010"},{"key":"2024030708001980000_51.1.39.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.38014"},{"key":"2024030708001980000_51.1.39.34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024030708001980000_51.1.39.35","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00296-015-3288-z","article-title":"Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: are there any differences between patients who relapsed and to those who remained in low disease activity?","volume":"35","author":"Almirall","year":"2015","journal-title":"Rheumatol Int"},{"key":"2024030708001980000_51.1.39.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew269"},{"key":"2024030708001980000_51.1.39.37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-020-00214-7","article-title":"Induction of sustained clinical remission in early axial spondyloarthritis following certolizumab pegol treatment: 48-week outcomes from C-OPTIMISE","volume":"7","author":"Landew\u00e9","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024030708001980000_51.1.39.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.3824"},{"key":"2024030708001980000_51.1.39.39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13075-019-1873-3","article-title":"Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study","volume":"21","author":"Moreno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024030708001980000_51.1.39.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.3675"},{"key":"2024030708001980000_51.1.39.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205202"},{"key":"2024030708001980000_51.1.39.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.4182"},{"key":"2024030708001980000_51.1.39.43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160363"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2023-0495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T16:01:17Z","timestamp":1709827277000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2023-0495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.3899\/jrheum.2023-0495"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2023-0495","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]}}}